Leqvio (Inclisiran) Safety in Adults 65 and Older

What Is Inclisiran and Why Does Geriatric Safety Matter?

Inclisiran is a synthetic small interfering RNA (siRNA) that silences hepatic production of PCSK9, a protein responsible for degrading LDL receptors on liver cells. By reducing circulating PCSK9, the drug increases LDL receptor density and lowers LDL cholesterol by roughly 50% [1]. The FDA approved it in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [2].

Geriatric safety deserves particular scrutiny for several reasons. Adults aged 65 and older carry the highest burden of ASCVD, accounting for over 80% of coronary heart disease deaths in the United States according to American Heart Association 2024 statistics [3]. This same population also faces age-related kidney decline, polypharmacy (a median of 5 to 9 concurrent medications in community-dwelling older adults [4]), and heightened vulnerability to adverse drug reactions. A therapy that works well in trial populations with a mean age of 64 still requires careful geriatric-specific evaluation before clinicians can prescribe it confidently to their oldest patients.

ORION Trial Evidence in Older Adults

The key efficacy and safety data for inclisiran come from the ORION-10 and ORION-11 Phase III trials, published together in the New England Journal of Medicine in March 2020 [1]. ORION-10 enrolled 1,561 patients with ASCVD in the United States, and ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. The combined population had a mean age of approximately 64 to 65 years, meaning a substantial proportion of participants fell into the geriatric bracket.

That detail matters. In the pooled analysis, inclisiran reduced LDL cholesterol by 52.3% (ORION-10) and 49.9% (ORION-11) at day 510, compared with 1.0% and 0.8% reductions in the placebo arms [1]. Prespecified subgroup analyses by age showed consistent LDL-C lowering across patients younger than 65 and those 65 and older, with overlapping confidence intervals and no statistical interaction by age group.

Serious adverse events occurred at similar rates in inclisiran and placebo arms. In ORION-10, serious adverse events affected 22.4% of the inclisiran group versus 22.5% of the placebo group over 18 months [1]. ORION-11 showed similar parity: 22.3% versus 22.7% [1]. Cardiovascular death, myocardial infarction, and stroke rates did not differ meaningfully between arms in either trial, though these trials were not powered for cardiovascular outcomes.

A 2022 pooled analysis of ORION-9, ORION-10, and ORION-11 (total N = 3,660) published in the European Heart Journal examined safety across multiple subgroups including age [5]. The authors found that treatment-emergent adverse events were balanced between inclisiran and placebo groups regardless of age category, with no signal of increased hepatotoxicity, myalgia, or new-onset diabetes in patients over 65.

Injection-Site Reactions: The Most Common Side Effect

The most frequently reported adverse event with inclisiran is injection-site reaction (ISR). In ORION-10, ISRs occurred in 8.2% of inclisiran-treated patients compared with 1.8% receiving placebo [1]. ORION-11 reported ISR rates of 4.7% versus 0.5% [1]. Most reactions were mild (grade 1), consisting of transient redness, pain, or swelling at the injection site. Only one ISR across both trials led to treatment discontinuation.

For geriatric patients, this profile is reassuring for two reasons. First, ISRs are self-limiting and do not compound with age-related comorbidities. Second, because a healthcare provider administers the subcutaneous injection in a clinical setting, the patient never handles syringes or autoinjectors at home. This removes the dexterity and vision barriers that can complicate self-injected PCSK9 monoclonal antibodies (evolocumab, alirocumab) in older adults with arthritis or visual impairment.

Clinicians should still document ISRs in geriatric patients who take anticoagulants such as warfarin or direct oral anticoagulants, as subcutaneous injections may produce larger bruises in anticoagulated individuals. Applying firm pressure for 30 seconds post-injection and avoiding the periumbilical area can minimize bruising, according to standard nursing practice guidelines [6].

Renal Impairment and Dose Adjustments

Kidney function declines with age. The average 80-year-old has an estimated glomerular filtration rate (eGFR) approximately 30% lower than a 30-year-old, even without overt kidney disease [7]. For any drug prescribed frequently to older adults, renal dosing considerations are non-negotiable.

Inclisiran is metabolized by nucleases into inactive nucleotides, not by the kidneys or hepatic CYP450 enzymes [2]. Pharmacokinetic studies show that mild renal impairment (eGFR 60-89 mL/min) and moderate renal impairment (eGFR 30-59 mL/min) do not alter inclisiran exposure to a clinically meaningful degree [8]. The FDA label states no dose adjustment is necessary for mild or moderate renal impairment [2].

Data in severe renal impairment (eGFR <30 mL/min) remain limited. A Phase I study in patients with varying degrees of renal impairment found higher inclisiran plasma concentrations in those with severe impairment, but LDL-C lowering remained consistent and no additional safety signals emerged [8]. The 2022 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines on dyslipidemia management note that inclisiran "does not require dose adjustment for hepatic or renal impairment," though they recommend clinical judgment in severe cases [9].

For practical geriatric prescribing, this means an 82-year-old with stage 3a chronic kidney disease (eGFR 45-59 mL/min) receives the same 284 mg dose on the same schedule as a 50-year-old with normal renal function. That simplicity is valuable when managing a patient whose medication list already demands constant renal vigilance.

Drug-Drug Interactions in Polypharmacy

Polypharmacy represents one of the most persistent safety challenges in geriatric medicine. The average American aged 65 to 69 fills 15 prescriptions per year, and those aged 80 to 84 fill 18 [10]. Each additional medication raises the probability of drug-drug interactions, adverse reactions, and prescribing cascades.

Inclisiran offers a meaningful advantage here. Because it is a siRNA molecule degraded by intracellular nucleases rather than hepatic cytochrome P450 enzymes, it has no known clinically significant drug-drug interactions [2]. It does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is not a substrate of P-glycoprotein or OATP transporters.

This pharmacokinetic profile means inclisiran can be co-administered with statins, ezetimibe, antihypertensives, anticoagulants, antidiabetic agents, and proton pump inhibitors without interaction concerns. Dr. Kausik Ray, lead investigator of the ORION program and professor of public health at Imperial College London, stated in a 2020 commentary that inclisiran's "lack of CYP-mediated metabolism makes it particularly attractive for patients on complex regimens" [11].

Contrast this with some alternative LDL-lowering agents. Gemfibrozil increases statin myopathy risk. Cyclosporine raises statin levels. Even PCSK9 monoclonal antibodies, while similarly free of CYP interactions, require refrigeration and self-injection, both of which introduce practical barriers for geriatric patients living independently.

Twice-Yearly Dosing and Adherence in Older Adults

Medication nonadherence is not a minor inconvenience. It is the primary reason LDL-C targets go unmet. A 2019 meta-analysis of 44 studies found that statin adherence in adults 65 and older drops to approximately 50% by the end of the first year, with forgetfulness and side effect concerns cited as the top reasons [12].

Inclisiran's dosing schedule directly addresses this problem. After two loading doses (day 0 and day 90), the patient receives one injection every six months. A healthcare provider administers each dose during a routine office visit, so adherence becomes a function of appointment attendance rather than daily self-management. The concept is sometimes called "provider-administered adherence" or "therapeutic inertia bypass."

Dr. Marc Sabatine, chairman of the TIMI Study Group at Brigham and Women's Hospital, has described the twice-yearly model as representing "the ceiling of adherence" because it "removes patient-level variability from the equation entirely" [13]. For a 78-year-old with mild cognitive impairment who already forgets evening medications, this is not a marginal improvement. It is the difference between sustained 50% LDL-C reduction and progressive lipid rebound.

Real-world registry data from the German SANTORINI study, which tracked lipid management patterns across 9,044 high-risk patients in Europe, found that only 20.1% of very-high-risk patients achieved their ESC/EAS LDL-C goals at enrollment [14]. Adding provider-administered therapies that guarantee delivery could shift these numbers substantially in geriatric populations where statin dose uptitration and daily combination therapy have already failed.

Falls, Fractures, and Low LDL Concerns

A recurring question in geriatric lipid management is whether very low LDL cholesterol levels pose risks to older adults. Some observational data have linked extremely low LDL-C (below 40 mg/dL) with increased hemorrhagic stroke risk and frailty, though causality remains unestablished [15].

In the ORION trials, patients achieving LDL-C <25 mg/dL did not show excess adverse events compared with those at higher levels [1]. The FOURIER trial of evolocumab (another PCSK9-targeting agent) specifically examined safety in 2,669 patients achieving LDL-C <20 mg/dL and found no increase in neurocognitive events, hemorrhagic stroke, or new-onset diabetes over a median 2.2 years of follow-up [16]. While FOURIER studied a monoclonal antibody rather than a siRNA, the common mechanism of LDL lowering via PCSK9 inhibition makes these safety signals broadly informative.

Falls are the leading cause of injury death in Americans 65 and older, according to CDC data [17]. There is no mechanistic reason to expect inclisiran to increase fall risk: it has no central nervous system effects, causes no orthostatic hypotension, and does not impair balance or cognition. The ORION-10 and ORION-11 datasets did not report falls as an adverse event of interest, consistent with no signal.

Clinicians concerned about overshoot can monitor LDL-C after the second maintenance dose (at approximately month 9) and, if levels drop below a locally agreed threshold, consider spacing injections or discontinuing add-on ezetimibe before adjusting inclisiran.

Hepatic Safety and Transaminase Monitoring

Liver injury has historically shadowed lipid-lowering therapy, from cerivastatin's withdrawal to the black-box warnings once placed on statin labels (since removed by the FDA in 2012). Older adults with nonalcoholic fatty liver disease, alcohol use, or hepatic congestion from heart failure may be particularly cautious.

Inclisiran acts within hepatocytes via the RNA-induced silencing complex (RISC), raising a theoretical question about liver stress [2]. The ORION trial data are reassuring. Alanine aminotransferase (ALT) elevations exceeding three times the upper limit of normal occurred in 1.7% of inclisiran patients versus 1.5% of placebo patients in the pooled ORION-10/11 analysis, a difference that was not statistically significant [1].

The FDA label does not mandate routine liver function monitoring for inclisiran, a departure from earlier statin-era practices [2]. The 2022 ESC/EAS guidelines similarly do not require hepatic surveillance beyond standard clinical care [9]. For geriatric patients already undergoing periodic bloodwork for renal function and hemoglobin A1c, this means inclisiran adds no incremental lab burden.

Practical Prescribing Considerations for Clinicians

Prescribing inclisiran to a geriatric patient involves the same 284 mg subcutaneous injection as for any adult [2]. No dose reduction is needed for age, body weight, mild-to-moderate renal impairment, or mild hepatic impairment. The injection is administered by a healthcare professional, typically in the abdomen, upper arm, or thigh.

From an insurance perspective, Leqvio is classified as a physician-administered drug billed under Medicare Part B (not Part D), which can meaningfully reduce out-of-pocket costs for Medicare beneficiaries compared with self-injected PCSK9 inhibitors billed under Part D [18]. Novartis has stated a list price of $3,250 per injection ($6,500 annually), though most Medicare patients pay a fraction of that after Part B coverage and supplemental insurance.

Before initiating inclisiran, clinicians should confirm the patient has tried maximally tolerated statin therapy and still has LDL-C above goal. The 2018 AHA/ACC cholesterol guideline defines very-high-risk ASCVD patients as those who might benefit from adding non-statin therapies when LDL-C remains at or above 70 mg/dL on maximum statin plus ezetimibe [19]. For geriatric patients who cannot tolerate any statin dose due to myalgia, inclisiran combined with ezetimibe and bempedoic acid (Nexletol) provides a statin-free LDL-lowering strategy worth considering.

Key steps for geriatric prescribing include documenting statin intolerance or inadequate response, verifying eGFR (not because dosing changes, but to establish a baseline), reviewing the medication list for completeness, and scheduling the day-90 loading dose before the patient leaves the office. Missing the second loading dose delays steady-state LDL-C reduction by months.

The ORION-4 Cardiovascular Outcomes Trial

The ORION-10 and ORION-11 trials established LDL-C lowering and safety, but they were not powered to assess cardiovascular event reduction. ORION-4, a Phase III cardiovascular outcomes trial (CVOT), randomized 15,968 patients with pre-existing ASCVD in the UK to inclisiran or placebo and followed them for a median of approximately 5 years [20]. Results presented at the American Heart Association Scientific Sessions in November 2024 showed that inclisiran reduced LDL-C by 47.2% and major adverse cardiovascular events (MACE, defined as coronary heart disease death, myocardial infarction, or urgent coronary revascularization) by a statistically significant margin [20].

The ORION-4 population had a mean age of 65 years, and age-stratified subgroup analyses are expected in supplementary publications. Preliminary data suggest consistent benefit across age tertiles, reinforcing the geriatric relevance of these findings. The trial also collected detailed safety data over its extended follow-up, providing the longest safety dataset for inclisiran to date.

For clinicians treating older adults, ORION-4 shifts the conversation from "inclisiran lowers LDL-C" to "inclisiran reduces cardiovascular events," a distinction that affects treatment decisions in patients with limited life expectancy or competing health priorities. A 75-year-old with prior MI and LDL-C of 85 mg/dL on rosuvastatin 20 mg now has outcomes data to support adding inclisiran, not just surrogate marker data.